<?php
include_once('../../includes/inc.php');
htmlHeader(array("title"=>"","metaDesc"=>"Dedicated to improve cancer outcomes via liquid biopsies.","preLoader"=>"0"));
?>
		<div class="main-container">
				<section class="image-bg pt240 pb240 pt-xs-180 pb-xs-180 parallax">
                                <div class="background-image-holder">
                                        <img alt="image" class="background-image " src="/img/geneFusion.jpg">
                                </div>
                                
                                <div class="container">
                                        <div class="row">
						<div class="col-sm-8">
							<h1 class="mb0 uppercase bold italic text-shadow">ALK Fusions<br>&amp; Resistance</h1>
							<h5 class="uppercase mb32 text-shadow">EML4 is not the only partner.</h5>
							<p class="lead mb0 text-shadow bold">FISH and IHC have shown to give discordant results and in one<br>study the use of FISH or IHC alone would have<br> <u>missed 25% of ALK-positive cases</u>.<sup>7</sup>
							</p>
						</div>
                                        </div>
                                        
                                </div>
                                
                        </section>
			<section>
                        <div class="container">
                            <div class="row v-align-children">
                                <div class="col-sm-4 col-md-4">
<p>Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase. Mutations in ALK have been noted for driving a variety of cancers. ALK fusions have been seen in non-small cell lung cancer (NSCLC)<sup>1</sup>, Ovarian cancer<sup>2</sup>, and colorectal cancer<sup>3</sup>. ALK fusions can occur in the entire ALK tyrosine kinase domain. Missense mutations in ALK have been found in some neuroblastomas<sup>4</sup>. Additionally, copy number gains have been observed in renal cell carcinoma<sup>5</sup> and rhabdomyosarcoma.</p>
                </p>
                                </div>
				<div class="col-sm-8">
					<table cellpadding="10" width="100%"><tr><td>
					Presented at ESMO 2016<br><a href="/publications/ResolutionBio_Ensartinib_ESMO2016.pdf" target="_new"><img src="/img/ResolutionBio_Ensartinib_ESMO2016.jpg"></a>
					</td><td>
					Presented at ASCO 2016<br><a href="/publications/ResolutionBio_Ensartinib_ASCO2016.pdf" target="_new"><img src="/img/ResolutionBio_Ensartinib_ASCO2016.jpg"></a>
					</td></tr></table>
				</div>
                            </div>
			</div>
		    </section>
		<section class="page-title page-title-3 image-bg overlay parallax">
                        <div class="background-image-holder">
                            <img alt="Background Image" class="background-image" src="/img/bloodcells.jpg">
                        </div>
                        <div class="container">
                            <div class="row">
                                <div class="col-sm-12 text-center">
                                    <h3 class="uppercase mb0">Gene Partner and Breakpoint Discovery</h3>
                                </div>
                            </div>
                            
                        </div>
                        </section>
		<section>
			<div class="row">
				<div class="col-sm-10 col-md-offset-1 mt0">
				<p>The ctDx platform has proven ability to discovery ALK gene fusions regardless of the fusion partner gene or breakpoint. The technology allows for the discovery of novel partners such as PRKAR1A or even fusions to non-coding regions. The assay also covers the tyrosine kinase domain of ALK where resistance mutations can occur, such as ALK C1156Y.</p>
<p>When tumor pathology is driven by ALK fusions, the tumor cells have been shown to be sensitive to ALK kinase inhibitors, such as crizotinib, and therefore have been recommended by the National Comprehensive Cancer Network (NCCN) for front-line therapeutic treatment of NSCLC patients.<sup>8</sup></p>
				</div>
			</div>
			<div class="row v-align-children">
				<img alt="ALK Fusions" src="/img/Xcovery_ALK.png">
			</div>
		</section>
		<section class="page-title page-title-3 image-bg overlay parallax">
                        <div class="background-image-holder">
                            <img alt="Background Image" class="background-image" src="/img/bloodcells.jpg">
                        </div>
                        <div class="container">
                            <div class="row">
                                <div class="col-sm-12 text-center">
                                    <h3 class="uppercase mb0">Resistance Mutations</h3>
                                </div>
                            </div>

                        </div>
                        </section>
		<section>
                        <div class="row">
                                <div class="col-sm-5 col-md-offset-1 mt0">
					<p>The assay also covers the entire tyrosine kinase domain of ALK where resistance mutations can occur. Additionally, the assay is able to detect ALK copy number amplifications (CNV).</p>
                                </div>
				<div class="col-sm-5">
					<div class="feature bordered mb30">
						<table class="table table-striped mutTable">
						<thead><tr><th>Canonical Resistance Mutations</th></tr></thead>
						<tbody><tr>
						<td class="gene">G1123S, 1151Tins, 1152P/R, C1156Y/T, I1171H/S/T/N, F1174C/L/V, V1180L, L1196M, L1198F, G1202R, G1202del, D1203N, S1206C/F/Y, G1210K, F1245C, F1269A/S, R1275Q, C1156Y+L1198F, F1174L+E1210K</td>
						</tr>
						</tbody>
						</table>
                                        </div>
				</div>
                        </div>
		</section>
			<div class="row">
		<div class="col-md-10 col-md-offset-1">
<hr>
<p class="footnotes"><sup>1</sup>
Choi et al. 2008 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/18593892">Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.</a><br>
Horn and Pao 2009 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/19667260">EML4-ALK: honing in on a new target in non-small-cell lung cancer.</a><br>
Koivunen et al. 2008 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/18594010">EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.</a></p>
<p class="footnotes"><sup>2</sup>Ren et al. 2012 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/22570254">Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer.</a></p>
<p class="footnotes"><sup>3</sup>Lin et al. 2009 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/19737969">Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.</a><br>
Lipson et al. 2012 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/22327622">Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.</a></p>
<p class="footnotes"><sup>4</sup>Chen et al. 2008 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/18923524">Oncogenic mutations of ALK kinase in neuroblastoma.</a></p>
<p class="footnotes"><sup>5</sup>Debelenko et al. 2011 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/21076462">Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum.</a><br>
Sukov et al. 2012 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/22743654">ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients.</a></p>
<p class="footnotes"><sup>6</sup>Choi et al. 2008 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/18593892">Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.</a><br>
Horn and Pao 2009 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/19667260">EML4-ALK: honing in on a new target in non-small-cell lung cancer.</a><br></p>
<p class="footnotes"><sup>7</sup>Cabillic et al. 2014 <a target="fn" href="http://www.ncbi.nlm.nih.gov/pubmed/24518086">Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.</a></p>
<p class="footnotes"><sup>8</sup>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) - Non-small cell lung cancer. Version 4.2015. <a href="http://www.nccn.org" target=_new>www.nccn.org</a>
		</div>
	</div>
                    </section>
</div>

<?php
footer();
?>
